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Summary
Atherosclerosis and its major complications –myocardial infarction and stroke– remain major 
causes of death and disability in the United States and world-wide. Indeed, with dramatic increases 
in obesity and diabetes mellitus, the prevalence and public health impact of cardiovascular 
diseases (CVD) will likely remain high. Major advances have been made in development of new 
therapies to reduce the incidence of atherosclerosis and CVD, in particular for treatment of 
hypercholesterolemia and hypertension. Oxidative stress is the common mechanistic link for many 
CVD risk factors. However, only recently have the tools existed to study the interface between 
oxidative stress and CVD in animal models. The most important source of reactive oxygen species 
(and hence oxidative stress) in vascular cells are the multiple forms of enzymes nicotinamide 
adenine dinucleotide phosphate oxidase (NADPH oxidase). Recently published and emerging 
studies now clearly establish that: 1) NADPH oxidases are of critical importance in atherosclerosis 
and hypertension in animal models; 2) given the tissue-specific expression of key components of 
NADPH oxidase, it may be possible to target vascular oxidative stress for prevention of CVD.
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Cardiovascular diseases (CVD) caused one death every 40 seconds (784,750 of 2,515,458 
deaths) in the United States in 2010 (1). Coronary heart disease (CHD) alone caused 
379,559 deaths in 2010, while 40.6% of CVD mortality is attributed to hypertension. Only 
54% of hypertensive patients using antihypertensive medications attain target levels of blood 
pressure. Although multiple risk factors lead to CHD, statins reduce morbidity and mortality 
risk more than any other preventive approach (2). Statins reduce LDL-cholesterol (3) and 
exert anti-inflammatory effects (4). However, statins are not well tolerated and uniformly 
effective in all patients (5,6), necessitating alternative pharmacological approaches for the 
treatment of CHD and hypertension.
Strong evidence suggests that altered redox signaling caused by increased bioavailability of 
reactive oxygen species (ROS) is a major contributor to the onset and/or progression of 
CVD, including atherosclerosis and hypertension (7,8). ROS include free radicals such as 
superoxide (O2•-) and hydroxyl radical (•OH), and nonradicals such as hydrogen peroxide 
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(H2O2). Atherosclerosis, an inflammatory disease, is the common cause of CVD and ROS 
play a critical role in the processes involved in atherogenesis. An important initial event in 
atherogenesis is increased endothelial permeability at sites of disturbed flow in the 
vasculature, which allows transcytosis of LDL into the subendothelial space of the arterial 
wall (9). The disturbed flow-triggered ROS generation causes endothelial cell activation and 
increases expression of cell surface adhesion molecules and cytokines, enabling the 
recruitment, adhesion, and transmigration of leukocytes into the subendothelial space (10). 
LDL is oxidized by ROS produced by all the activated major cells in the arterial wall, 
including endothelial cells, smooth muscle cells, and macrophages (11). Activated aortic 
wall cells also produce proinflammatory secretory phospholipase A2 which hydrolyzes 
phospholipids in LDL, increasing its affinity to arterial proteoglycans and causing 
lipoprotein aggregation and accumulation (12,13). Oxidized LDL is ingested by 
macrophages forming foam cells which combine with leukocytes, generating the fatty 
streaks that develop into plaques over time.
In addition, ROS-induced endothelial dysfunction affects CVD by decreasing endothelium-
dependent vasodilation. Oxidative stress plays a major role in endothelial dysfunction as 
superoxide can react with nitric oxide (•NO), forming peroxynitrite and reducing the 
bioavailability of •NO which has anti-inflammatory and vasodilatory functions. 
Peroxynitrite, a potent oxidant itself, can oxidize small-molecule antioxidants such as 
glutathione and tetrahydrobiopterin (14,15). Decreased bioavailability of 
tetrahydrobiopterin, an essential cofactor for endothelial nitric oxide synthase, makes the 
enzyme transfer electrons from NADPH to oxygen instead of its substrate L-arginine, 
causing eNOS uncoupling and producing superoxide instead of NO. Uncoupling of eNOS is 
an important contributor to hypertension (16,17). Furthermore, peroxynitrite also oxidizes 
the enzyme dimethylarginine dimethylaminohydrolase, which metabolizes asymmetric 
dimethylarginine, an endogenous inhibitor of eNOS, resulting in elevated levels of the 
inhibitor and decreased •NO synthesis (18).
Besides oxidizing LDL and inducing inflammation and endothelial dysfunction, ROS play a 
major role in vascular remodeling. A major contributor to vascular remodeling under 
oxidative stress conditions is the phenotypic modulation of vascular smooth muscle cells, 
which includes loss of contractility, increased proliferation and migration and enhanced 
production of extracellular components such as collagen and fibronectin (19,20). 
Extracellular matrix metalloproteinases, enzymes involved extracellular matrix turnover, are 
activated by ROS-induced oxidation (21). For example, activation of MMP-2 is correlated 
with elastic fiber fragmentation which contributes to the stiffening of the arterial vasculature 
(22). Whereas moderate levels of ROS promote VSMC proliferation excess ROS production 
induces VSMC apoptosis (20). We have shown that increase in collagen I expression, 
impaired elastic lamellae integrity, and increased medial VSMC apoptosis under chronic 
oxidative stress conditions cause aortic stiffening, an independent risk factor for CVD (23). 
Furthermore, oxidative stress-induced MMP activation and increased VSMC apoptosis may 
render atherosclerotic plaques more susceptible to rupture, increasing the risk of acute 
coronary syndromes (9,24).
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The sources of increased ROS production include damaged or dysfunctional mitochondria 
and enhanced synthesis or activation of the enzymes nicotinamide adenine dinucleotide 
phosphate oxidase (NADPH oxidase), xanthine oxidase, lipoxygenases, myeloperoxidase, 
and cytochrome P450 oxidases and an uncoupled endothelial nitric oxide synthase. The 
NADPH oxidases generate ROS as the main function of their activity, whereas other 
enzymes generate ROS as byproducts of their catalytic function.
NADPH Oxidases
NADPH oxidases are a family of transmembrane proteins which are oxygen- and NADPH-
dependent oxidoreductases that produce O2•- and/or H2O2 in various cell types and tissues, 
often in response to hormones, growth factors and immune mediators (25–27). The classical 
phagocytic enzyme has flavocytochrome b558, a transmembrane catalytic core, composed of 
Nox2 and p22phox proteins and the cytosolic regulatory proteins p47phox, p40phox, 
p67phox, and small G-protein Rac1 or Rac2 (Figure 1). In response to microbial exposure or 
inflammatory mediators, the cytosolic proteins assemble with the catalytic core in the 
membrane, in part mediated by phosphorylation of p47phox and GTP binding to Rac, 
activating the enzyme.
The mammalian NADPH oxidase family includes seven isoforms: Nox1, Nox2, Nox3, 
Nox4, Nox5, Duox1, and Duox2 (26,27). Nox1-4 have similar predicted domain structure 
with six α-helical transmembrane domains in the N-terminus and a cytoplasmic C-terminus 
dehydrogenase domain containing conserved binding sites for FAD and NADPH. Nox4 is 
constitutively active as it does not possess cytosolic regulatory subunits and calcium-binding 
EF hands (Figure 1). NoxO1 and NoxA1, the homologs of p47phox and p67phox, 
respectively, and Rac1 are the cytosolic regulatory subunits for Nox1 (Figure 1). However, 
Nox1 activity involves interaction of p47phox with NoxA1 in mouse vascular smooth 
muscle cells (VSMC), indicating that NADPH oxidase subunit expression and composition 
may vary in various vascular beds and species (28,29). Only Nox1, Nox2, Nox3, and Nox4 
require association with p22phox for enzyme activity (30). Nox5 is distinct from Nox1-4 by 
containing a calmodulin-like EF domain in the N-terminus with four Ca2+-binding sites 
(Figure 1). The Duox (dual oxidase) enzymes are similar to Nox5 in possessing an EF 
domain, but also contain an additional N-terminus transmembrane α-helix, followed by an 
extended extracellular domain that shares ~20% identity to myeloperoxidase at the amino 
acid level (30). Nox5 and the Duox enzymes are constitutively active and do not require 
cytosolic proteins for activity. Furthermore, they are acutely activated by elevated cellular 
calcium levels via their EF domain in response to receptor-linked stimuli.
Nox isoform expression varies among different cell types of the systemic and renal 
vasculature, often with more than one isoform expressed in various cell types (7,27). Nox1 is 
mainly expressed in VSMCs whereas Nox2 is present in endothelial cells and fibroblasts of 
the arterial wall. However, expression of Nox1 in endothelial cells and fibroblasts and Nox2 
in human resistance arteries was also reported (31). Nox4 is expressed in all the vascular 
wall cells—VSMCs, endothelial cells, and fibroblasts (26,32). Nox5 is present in human 
VSMCs and endothelial cells, but is absent in rodents (33). Duox1 expression was observed 
in the human aortic VSMCs.
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In the kidney, Nox1 is expressed in the rat renal cortex (18), and glomerular mesangial cells 
(35). In addition, p22phox, p67phox, Nox2, and Nox4 protein expression was observed in 
rat renal cortex. Chabrashvili et al. (36) reported p22phox, Nox2, p67phox, and p47phox 
expression in afferent arterioles as well as in macula densa by immunochemical staining. 
While mesangial cells contain Nox4, p22phox, p47phox, and p67phox, podocytes express 
Nox2, p22phox, p47phox, and p67phox. Nox2, Nox4, p22phox, and p47phox expression 
was observed in human arcuate and interlobular arteries (37).
Activation of Nox1, Nox2, Nox3, and Nox5 results in increased O2•- generation while Nox4 
predominantly produces H2O2. NADPH oxidase-derived ROS generation could be 
extracellular and/or intracellular, depending on the subcellular localization of the Nox 
isoform (38). Subcellular localization at which Nox isoforms are expressed include plasma 
membrane, endosome, caveolae, endoplasmic reticulum, mitochondria, and nucleus.
NADPH Oxidase 1
Nox1 NADPH oxidase regulates proliferation and migration of VSMC, processes which 
potentiate atherogenesis by promoting vascular remodeling (39,40). Increase in Nox1 and 
p22phox expression was observed early after balloon injury of carotid artery (41), whereas 
Nox1 deficiency attenuated wire injury-induced neointima formation in femoral artery (39). 
Sheehan et al. (42) reported that Nox1 activation is an important contributor to experimental 
atherosclerosis as ApoE−/−/Nox1-/y mice had significantly decreased aortic atherosclerotic 
lesion area and macrophage content in aortic sinus area compared with ApoE−/−, when they 
were fed a high-fat diet (Figure 1, Table 1).
Our data support the important role of Nox1 NADPH oxidase in atherosclerosis as 
overexpression of Nox1 activator protein NoxA1 increased neointimal hyperplasia in injured 
mouse carotid arteries (28). In addition, aortas and atherosclerotic lesions of ApoE−/− mice 
and human carotid atherosclerotic lesions express increased NoxA1 protein level. Lending 
further support to the role of Nox1 in atherogenesis, GKT136901, a Nox1 and Nox4 
inhibitor, decreased ROS generation and atherosclerosis and attenuated the expression of 
adhesion protein CD44 and its principal ligand hyaluronan in atherosclerotic lesions (43) 
(Figure 2).
Nox1 also plays a key role in diabetes-accelerated atherosclerosis. GKT137831, another 
Nox1/4 inhibitor, prevented diabetes-mediated increase in atherosclerotic lesion area in 
ApoE−/− mice by attenuating vascular T cell infiltration, ROS levels and markers of 
inflammation, and necrotic area (44) (Figure 1, Table 1). This effect is mediated through 
Nox1, but not Nox4, as only deletion of Nox1 decreased atherosclerosis, vascular ROS 
levels, expression of chemokines, proinflammatory and profibrotic markers, and infiltration 
of macrophages (45).
Evidence from experimental models of hypertension such as those induced by angiotensin II 
(Ang II) and deoxycorticosterone acetate (DOCA-salt), renovascular hypertension, and 
spontaneously hypertensive rats support the role of vascular NADPH oxidases in regulating 
blood pressure (7,8). Support for the role of Nox1 NADPH oxidase activity in Ang II-
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induced hypertension is evident from the use of genetically altered mice. Increase in ROS 
levels and blood pressure in response to Ang II infusion were significantly blunted in 
Nox1-/y mice (46,47) (Figure1, Table 1). L-NAME, a nitric oxide synthase inhibitor, 
abolished the pressor response to Ang II in these mice, suggesting that preservation of the 
availability of •NO because of the depletion of Nox1-derived ROS is the underlying 
mechanism (47). Complementing the Nox1 deletion studies, Ang II infusion in transgenic 
mice overexpressing Nox1 in VSMCs increased vascular O2•- production, decreased •NO 
bioavailability, impaired vasorelaxation, and elevated systolic blood pressure (46,48).
NADPH Oxidase 2
Judkins et al. (49) reported increased Nox2 expression and ROS levels in the aortic 
endothelium of ApoE−/− mice before the appearance of atherosclerotic lesions. 
Complimenting this observation, ApoE−/−/Nox2-/y on high-fat diet had decreased aortic ROS 
production with increased •NO bioavailability and a 50% reduction in aortic atherosclerotic 
lesion area compared with the ApoE−/− mice. Supporting the role of Nox2 in atherogenesis, 
Nox2-/y mice had decreased leukocyte infiltration and reduced neointima formation in 
response to arterial injury compared with the wild-type (50) (Figure 1). Nox2 NADPH 
oxidase is involved in endothelial dysfunction and the development of renovascular 
hypertension (51), and Nox2-/y mice had significantly decreased afferent arteriolar tone and 
reactivity to Ang II (52). Analogous to this, spontaneously hypertensive rats (SHR) had a 
10-fold increase in Nox2 mRNA expression, a 3-fold increase in O2•- production, and 
strongly diminished response to acetylcholine (53). Nox2-dependent NADPH oxidase 
activity is the main source of O2•- production in human renal proximal resistance arteries 
which could impact long-term arterial pressure control (37).
Aortic p22phox expression and NADPH oxidase activity were upregulated in rats infused 
with Ang II (54). Antihypertensive agents losartan and hydralazine inhibited increase in 
p22phox expression and NADPH oxidase activity, whereas infusion of recombinant heparin-
binding superoxide dismutase decreased both blood pressure and p22phox expression, 
suggesting that activation of NADPH oxidase system plays a key role in hypertension (Table 
1). Congruent with this, Chabrashvilli et al. (55) reported that Ang II infusion increases 
oxidative stress via Ang II type 1 receptor by upregulating the expression of p22phox and 
Nox1 in the renal cortex.
We showed decreased O2•- production and proliferative response to growth factors in 
p47phox−/− VSMC compared with the wild-type cells (56). Furthermore, ApoE−/−/
p47phox−/− had significantly less atherosclerosis than ApoE−/− mice, both on standard chow 
and high-fat diet (56,57) (Figure 3). The decrease in aortic atherosclerotic burden and 
diminished neointimal hyperplasia in response to arterial injury in the ApoE−/−/p47phox−/− 
mice is associated with reduced CD44 adhesion molecule expression (57). Using allogenic, 
sex-mismatched bone marrow transplantation, we also showed that the atheroprotective 
effect of p47phox deletion in ApoE−/− mice is caused by the inhibition of NADPH oxidase 
activity in monocytes/macrophages as well as vascular wall cells (58).
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Experimental models also support the role of p47phox-dependent NADPH oxidase in 
hypertension. In the kidney of SHR rat, p47phox mRNA and protein expression were 
significantly increased in the vasculature, macula densa, and distal nephron, preceding 
hypertension (36). Hypertensive response to Ang II infusion and vascular O2•- production 
were markedly blunted in p47phox−/− compared with the wild-type mice (59). Consistent 
with the decrease in Ang II-induced mean arterial pressure, afferent arterioles in p47phox−/− 
mice had significantly decreased ROS levels and myogenic contraction response to Ang II 
(60) (Figure 4).
Underscoring the clinical relevance of Nox2 NADPH oxidase in human atherosclerosis, 
Sorescu et al. (61) reported increased O2•- generation and Nox2 and p22phox expression in 
the shoulder region of atherosclerotic plaque, which were associated with the severity of 
atherosclerosis. Interestingly, Nox4 expression is upregulated in atheromas containing an 
abundance of VSMC, whereas it is downregulated in more advanced plaques characterized 
by fibrosis and reduction in intimal SMC. Furthermore, p22phox expression and ROS 
generation were increased with atherosclerosis progression in coronary arteries and were 
significantly higher in unstable angina pectoris compared with stable angina pectoris 
(62,63). Simultaneous intravascular ultrasound and immunohistochemistry analyses indicate 
that p22phox-dependent NADPH oxidase-derived ROS significantly contribute to coronary 
atherogenesis and arterial remodeling associated with plaque vulnerability (64).
NADPH Oxidase 4
Using ApoE−/ −/LDLR−/ − mice, Xu et al. (65) showed that Nox4 expression was increased 
in advanced aortic atherosclerosis lesions, which is associated with increased ROS 
generation, cell cycle arrest, senescence, and increased susceptibility to apoptosis in SMC. 
Furthermore, Nox4 overexpression in aortic SMC recapitulated SMC phenotype seen in 
advanced atherosclerotic lesions, suggesting that increased Nox4 expression in advanced 
lesions may cause plaque instability. Strong experimental evidence is lacking for a role of 
Nox4 NADPH oxidase in hypertension. However, Shah and colleagues reported that 
transgenic mice with endothelial-specific Nox4 overexpression have greater acetylcholine-
induced vasodilation and significantly lower basal systemic blood pressure than the wild-
type littermates (66) (Table 1). The increased vasodilatory response was attributed to 
increased H2O2 production and H2O2-induced hyperpolarization.
NADPH Oxidase 5
Growth factor and hormone induced Nox5 activation increases human endothelial cell and 
aortic SMC proliferation by modulating redox-sensitive mitogenic signaling pathways (67–
69). Supporting this data, Guzik et al. (70) reported significantly increased Nox5 mRNA and 
protein expression and increased ROS generation in the coronary arteries of CAD patients. 
Nox5 expression was increased in the endothelium in the early lesions and in VSMC in the 
advanced lesions (Figure 1, Table 1). The beneficial effect of calcium channel antagonists in 
the treatment of angina and CAD was attributed to diminished Nox5 activation in cells 
harboring L-type calcium channels, including VSMC in lesions.
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Conclusions
In conclusion, accumulating data from experimental and NADPH oxidase deficiency animal 
models and human studies strongly support a role for NADPH oxidases in vascular 
homeostasis and disease. Evolving consensus suggests that decreasing oxidative stress by 
targeting specific sources of ROS such as NADPH oxidases might yield new therapies for 
the treatment of atherosclerosis and hypertension. The tissue-specific variations in the 
composition of various NADPH oxidases could provide an opportunity to develop specific 
small molecule inhibitors of these enzymes to treat CVD, with fewer off-target effects. 
Advances in drug delivery vehicles and vascular imaging techniques along with the 
availability of specific small molecule inhibitors of NADPH oxidase isoforms may 
transform the treatment of atherosclerosis and hypertension.
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Figure 1. 
The critical role of NADPH oxidases in atherosclerosis, diabetic atherosclerosis, and 
hypertension as evident from mouse models, NADPH oxidase inhibitors and human data.
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Figure 2. 
GKT136901, a Nox1/Nox4 oxidase inhibitor, decreased atherosclerosis and attenuated ROS 
generation, plasma 8-isoprostane levels, and CD44 and hyaluronan expression in 
atherosclerotic lesions. Reprinted from reference 27, with permission from Journal of 
Biological Chemistry.
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Figure 3. 
ApoE−/−/p47phox−/− express less CD44 in atherosclerotic lesions (A) and have decreased 
aortic root lesion area compared with ApoE−/− mice (B). Reprinted from reference 41, with 
permission from Circulation Research.
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Figure 4. 
Mean arterial pressure is decreased in p47phox−/− compared with the wild-type mice in 
response to Ang II infusion: daytime (asleep) A; nighttime (awake) B. Reprinted from 
reference 44, with permission from Hypertension.
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Table 1
The role of NADPH oxidases in atherosclerosis, hypertension, and diabetes-accelerated atherosclerosis
Effector Genetic model / pharmacologic
agent
Phenotype Ref.
Mouse/Rat model
Nox1 Nox1−/y/ApoE−/− Decreased atherosclerosis 42
Nox1−/y Blunted BP elevation induced by Ang II 46,47
ApoE−/−, diabetes, GKT137831 Decreased diabetes-accelerated atherosclerosis 44,45
Nox1/Nox4 GKT136901 Decreased atherosclerosis and decreased CD44 expression and 
hyaluronan levels in atherosclerotic lesions
43
NoxA1 ApoE−/−, NoxA1 overexpression Increased atherosclerosis in ApoE−/− mice 28
Nox2 Nox2−/y/ApoE−/− Decreased atherosclerosis 49
Nox2−/y Decreased chronic Ang II infusion elevated blood pressure 52
SHR rat Increased Nox2 mRNA 53
p22phox Rat Ang II induced p22phox and Nox1 mRNA expression 55
Rat Ang II-induced hypertension 54
p47phox p47phox−/−/ApoE−/− Decreased CD44 and atherosclerosis 56,57
SHR rat Increased p47phox mRNA 36
p47phox−/− Blocked Ang II-induced ROS and hypertension 59
p47phox−/− Decreased the sensitivity of Ang II to induce BP response 60
Nox4 ApoE−/−/LDLR−/−, aged mice Atherosclerotic plaque instability 65
Endothelium-targeted Nox4 TG Decreased systemic blood pressure 66
Clinical data
Nox2 Human renal proximal resistance arteries Decreased endothelium-dependent vasodilation 37
Nox2/p22phox Human coronary artery Severity of atherosclerosis 61
p22phox Human coronary artery Increased expression is correlated with atherosclerosis 62,64
Nox5 Human endothelial cells and VSMC Elevated in endothelium of atherosclerotic aortas 69
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